Ji D X, Tan J R, Yu H W
Pulmonary and Critical Care Medicine, Huzhou Central Hospital, Huzhou 313000, China.
Department of Otorhinolaryngology, Huzhou Central Hospital, Huzhou 313000, China.
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2019 Dec 7;54(12):894-901. doi: 10.3760/cma.j.issn.1673-0860.2019.12.003.
By use of Meta analysis to compare efficacy, safety and compliance of subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) on allergic rhinitis (AR). Cochrane Library, Pubmed, Embase, CNKI Database, Wan Fang and Chinese Sci-tech Journal Database (from established time to May of 2018) were searched for trials about the AR treated by SCIT and SLIT. The relevant literatures were screened, and the randomized controlled studies were chosen. Nasal symptom scores, visual analogue scale (VAS) scores, adverse reactions and compliance were used as the outcome indicators, and the methodological quality of the literatures was evaluated strictly. The extracted data were analyzed by RevMan 5.3 and Stata 14 software. A total of 20 randomized controlled studies were included, the overall quality of which was relatively high. No publication bias was found. There was no significant difference in nasal symptom scores, VAS scores and compliance between SCIT and SLIT ( value was 0.03, 0.14, respectively, 1.12; 95 value was -0.17-0.23, -0.03-0.31, 0.92-1.35, respectively, all 0.05); SLIT group resulted in lower overall incidence of adverse reactions than that of SCIT group (1.79, 95: 1.42-2.26, 0.05). Both SCIT and SLIT have similar eppecacy and compliance for treatment of AR, while adverse reactions are more frequently observed in SCIT.
采用Meta分析比较皮下免疫疗法（SCIT）和舌下免疫疗法（SLIT）治疗变应性鼻炎（AR）的疗效、安全性及依从性。检索Cochrane图书馆、Pubmed、Embase、中国知网数据库、万方数据库及中国科技期刊数据库（建库至2018年5月）中关于SCIT和SLIT治疗AR的试验。筛选相关文献，选取随机对照研究。以鼻症状评分、视觉模拟量表（VAS）评分、不良反应及依从性作为结局指标，并严格评估文献的方法学质量。采用RevMan 5.3和Stata 14软件对提取的数据进行分析。共纳入20项随机对照研究，其总体质量较高。未发现发表偏倚。SCIT和SLIT在鼻症状评分、VAS评分及依从性方面差异无统计学意义（ 值分别为0.03、0.14、1.12；95% 可信区间分别为-0.170.23、-0.030.31、0.921.35，均P>0.05）；SLIT组不良反应总发生率低于SCIT组（ =1.79，95% 可信区间：1.422.26，P<0.05）。SCIT和SLIT治疗AR的疗效及依从性相似，但SCIT不良反应更常见。
